GE HealthCare Technologies Inc. (NASDAQ:GEHC) Stake Decreased by SeaCrest Wealth Management LLC

SeaCrest Wealth Management LLC lessened its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 6.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,106 shares of the company’s stock after selling 1,067 shares during the period. SeaCrest Wealth Management LLC’s holdings in GE HealthCare Technologies were worth $1,259,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in GEHC. Rosenberg Matthew Hamilton raised its holdings in GE HealthCare Technologies by 117.4% during the fourth quarter. Rosenberg Matthew Hamilton now owns 711 shares of the company’s stock worth $56,000 after purchasing an additional 384 shares in the last quarter. Signal Advisors Wealth LLC raised its holdings in GE HealthCare Technologies by 1.5% during the fourth quarter. Signal Advisors Wealth LLC now owns 13,764 shares of the company’s stock worth $1,076,000 after purchasing an additional 210 shares in the last quarter. Miracle Mile Advisors LLC bought a new stake in GE HealthCare Technologies during the fourth quarter worth approximately $240,000. Bar Harbor Wealth Management raised its holdings in GE HealthCare Technologies by 6.6% during the fourth quarter. Bar Harbor Wealth Management now owns 26,784 shares of the company’s stock worth $2,094,000 after purchasing an additional 1,648 shares in the last quarter. Finally, Bridge Creek Capital Management LLC raised its holdings in GE HealthCare Technologies by 10.3% during the fourth quarter. Bridge Creek Capital Management LLC now owns 11,729 shares of the company’s stock worth $917,000 after purchasing an additional 1,092 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

GEHC has been the topic of several recent analyst reports. Wells Fargo & Company boosted their target price on GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an “overweight” rating in a report on Thursday, October 31st. BTIG Research raised GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 target price on the stock in a report on Wednesday, September 18th. Evercore ISI lifted their price target on shares of GE HealthCare Technologies from $98.00 to $102.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. UBS Group lowered shares of GE HealthCare Technologies from a “neutral” rating to a “sell” rating and decreased their price target for the stock from $84.00 to $74.00 in a research report on Thursday, September 26th. Finally, Stifel Nicolaus lifted their price target on shares of GE HealthCare Technologies from $100.00 to $102.00 and gave the stock a “buy” rating in a research report on Monday, September 30th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.00.

Insider Buying and Selling at GE HealthCare Technologies

In other GE HealthCare Technologies news, CEO Roland Rott sold 3,577 shares of GE HealthCare Technologies stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $86.48, for a total transaction of $309,338.96. Following the completion of the sale, the chief executive officer now owns 24,298 shares of the company’s stock, valued at $2,101,291.04. This trade represents a 12.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.27% of the company’s stock.

GE HealthCare Technologies Trading Down 0.6 %

NASDAQ GEHC opened at $83.66 on Thursday. GE HealthCare Technologies Inc. has a twelve month low of $71.31 and a twelve month high of $94.55. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.98 and a current ratio of 1.23. The stock has a market cap of $38.22 billion, a price-to-earnings ratio of 22.98, a PEG ratio of 2.90 and a beta of 1.11. The firm’s 50 day moving average price is $82.13 and its two-hundred day moving average price is $84.27.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $1.06 by $0.08. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The firm had revenue of $4.86 billion for the quarter, compared to analysts’ expectations of $4.87 billion. During the same period in the previous year, the company posted $0.99 EPS. The company’s quarterly revenue was up .9% compared to the same quarter last year. Equities analysts anticipate that GE HealthCare Technologies Inc. will post 4.3 EPS for the current year.

GE HealthCare Technologies Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Tuesday, January 14th will be paid a dividend of $0.035 per share. The ex-dividend date is Tuesday, January 14th. This represents a $0.14 dividend on an annualized basis and a dividend yield of 0.17%. This is a positive change from GE HealthCare Technologies’s previous quarterly dividend of $0.03. GE HealthCare Technologies’s dividend payout ratio (DPR) is 3.85%.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.